Initiation of the Phase 3 program expands Ionis’ late-stage pipeline to 7 medicines in 9 indications CARLSBAD, Calif. , Feb. 1, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. ( Nasdaq : IONS) today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies
Read more